Callan JMB Signs Manufacturing Oversight, Federal Deployment, and Commercialization Agreement of Multi-Asset Therapeutic Pipeline with Attune for Approximately $50 to $75 Million in Total Revenue

Stock Information for Callan JMB Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Callan JMB Inc.

Callan JMB Announces Participation in the DealFlow Discovery Conference on January 28-29, 2026
Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility
Callan JMB Announces Third Quarter 2025 Financial Results and Provides Business Update
Callan JMB Enters Agreement to Install Oral Drug Delivery Equipment in Texas Facility
Callan JMB Expands Logistics Platform Into Food Sampling Sector, Advancing Multi-Variant Growth Strategy
Callan JMB Upgrades Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature Monitoring
Callan JMB Announces Participation in the LD Micro Main Event XIX Conference on October 19-21, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.